Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech Biologics and Vaccine Company.
Eli Lilly’s dealmaking team must have a “that was easy” Staples button.
The world’s most valuable healthcare company and maker of the biggest-selling medicine globally …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lilly dives into vaccine research with 3 biotech buyouts
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Eli Lilly acquires three vaccine developers for $3.8 billion
Eli Lilly to buy three small vaccine developers
Eli Lilly spending $3.8 billion to buy vaccine makers
What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)
Eli Lilly comprará 3 empresas fabricantes de vacunas por casi 4 mil mdd; ampliará investigación de enfermedades infecciosas | El Universal
Eli Lilly acquires Engage Biologics for up to $202 million
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an…
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling…
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss…
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
